natgillin/translations-raw huggingface dataset:
A QTcF interval of > 500 ms (confirmed by repeat electrocardiogram).
QTcF interval od > 500 ms (potvrđen ponovljenim elektrokardiogramom).
A questionnaire to gather detailed ADR report documentation.
upitnik za prikupljanje detaljne dokumentacije o prijavi nuspojave na lijek,
a RA study I at 24 weeks, RA study II at 26 weeks , and RA study III at 24 and 52 weeks b 40 mg Humira administered every other week c MTX = methotrexate
a Ispitivanje RA I nakon 24 tjedna, ispitivanje RA II nakon 26 tjedana, ispitivanje RA III nakon 24 tjedna i nakon 52 tjedna b 40 mg lijeka Humira primijenjenog svaki drugi tjedan c MTX = metotreksat
A randomised and controlled clinical trial (EGF114299) in a patient population essentially identical to that of EGF30008 except that subjects must have received prior treatment with trastuzumab, with aromatase inhibitor (AI) + trastuzumab included as the reference arm.
Randomiziranog i kontroliranog kliničkog ispitivanja (EGF114299) na populaciji bolesnika koja je u osnovi istovjetna populaciji iz EGF30008, s time da su ispitanici morali primiti prethodnu terapiju trastuzumabom, a uključena je i referentna skupina koji prima inhibitor aromataze i trastuzumab.
A randomised double-blind morbidity-mortality study called the Antihypertensive and Lipid- Lowering treatment to prevent Heart Attack Trial (ALLHAT) was performed to compare newer therapies: amlodipine 2.5-10 mg/day (calcium channel blocker) or lisinopril 10-40 mg/day (ACE- inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/day in mild to moderate hypertension.
Randomizirano dvostruko slijepo ispitivanje pobola smrtnosti pod nazivom Antihipertenzivno ispitivanje i liječenje snižavanja lipida a u cilju sprečavanja srčanog udara (ALLHAT) provedeno je da bi se usporedile novije terapije: amlodipin 2,5-10 mg/dan (blokator kalcijevih kanala) ili lizinopril 10-40 mg/dan (ACE-inhibitor ) kao terapije prve linije s terapijom tiazidnim diuretikom, klortalidonom 12,5-25 mg/dan u blagoj do umjerenoj hipertenziji.
A randomised, double blind, placebo-controlled phase II study (RISE-IIP) to evaluate the efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) was terminated early.
Randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje faze II (RISE-IIP) u kojem su se ocjenjivale djelotvornost i sigurnost riocigvata u bolesnika sa simptomatskom plućnom hipertenzijom povezanom s idiopatskim intersticijskim pneumonijama (PH-IIP) prekinuto je ranije.
A randomised, double-blind, multi-centre, placebo-controlled phase III trial (study RRA02997) has been conducted in 203 adult patients (inhaled iloprost at the concentration of 10 microgram/ml: N=101; placebo n=102) with stable pulmonary hypertension.
Randomizirano, dvostruko slijepo, multicentrično, placebo kontrolirano ispitivanje faze III (ispitivanje RRA02997) provedeno je na 203 odrasla bolesnika (inhalirani iloprost pri koncentraciji od 10 mikrograma/ml: N = 101, placebo n = 102) sa stabilnom plućnom hipertenzijom.
A randomised, double-blind, multi-national, placebo controlled, phase III study (PATENT-1) was conducted in 443 adult patients with PAH (riociguat individual dose titration up to 2.5 mg three times daily: n=254, placebo: n=126, riociguat “capped” dose titration (CT) up to 1.5 mg (exploratory dose arm, no statistical testing performed; n=63)).
Randomizirano, dvostruko slijepo, multinacionalno, placebom kontrolirano ispitivanje faze III (PATENT-1) bilo je provedeno u 443 odraslih bolesnika s PAH-om (titracija pojedinačne doze riocigvata do 2,5 mg tri puta na dan: n=254, placebo: n=126, riociguvt titriran do“ograničene” doze do 1,5 mg (krak koji je primao eksplorativnu dozu, bez provedenog statističkog testiranja; n=63).
A randomised, double-blind, parallel-group non-inferiority study compared the relative efficacy of two different daily maintenance doses of leflunomide, 10 mg and 20 mg.
Randomiziranim, dvostruko slijepim, neinferiornim ispitivanjem paralelnih skupina uspoređivala se relativna djelotvornost dviju različitih dnevnih doza održavanja leflunomida, odnosno 10 i 20 mg.
A randomised, double-blind, parallel-group non-inferiority study compared the relative efficacy of two different daily maintenance doses of leflunomide, 10 mg and 20 mg.
Randomiziranom, dvostruko slijepom, neinferiornom studijom paralelnih grupa uspoređivala se relativna djelotvornost dviju različitih dnevnih doza održavanja leflunomida, odnosno 10 i 20 mg.
A randomised, double-blind, parallel-group non-inferiority study compared the relative efficacy of two different daily maintenance doses of leflunomide, 10 mg and 20 mg.
Randomiziranom, dvostruko slijepom, neinferiornom studijom paralelnih grupa uspoređivala se relativna učinkovitost dviju različitih dnevnih doza održavanja leflunomida, odnosno 10 i 20 mg.
A randomised, double-blind, placebo-controlled study was conducted in 278 patients with primary pulmonary hypertension, PAH associated with connective tissue disease, and PAH following surgical repair of congenital heart lesions.
Randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno je u 278 bolesnika s primarnom plućnom hipertenzijom, PAH-om povezanim s bolešću vezivnog tkiva i PAH-om koji je nastao nakon kirurškog popravka prirođenih srčanih lezija.
A randomised, double-blind, placebo-controlled study was conducted in 405 patients with pulmonary arterial hypertension.
Randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno je u 405 bolesnika s plućnom arterijskom hipertenzijom.
A randomised, evaluator-blind, controlled study was completed in HIV-infected patients with azole- susceptible oropharyngeal candidiasis (most patients studied had C. albicans isolated at baseline).
Provedeno je randomizirano kontrolirano ispitivanje u bolesnika zaraženih HIV-om s kandidijazom usta i ždrijela osjetljivom na azole (u većine je bolesnika na početku ispitivanja izolirana C. albicans), u kojemu ocjenitelji nisu znali koja je terapija dodijeljena kojem bolesniku.
A randomised, open-label cross-over study was performed in children and adolescents with asthma (aged 4- 17 years), adults with asthma (aged 18-45 years), adults with chronic obstructive pulmonary disease (COPD) (aged older than 55 years) and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device (containing placebo).
Randomizirano, otvoreno ukriženo (engl. cross-over) ispitivanje bilo je provedeno u djece i adolescenata s astmom (u dobi od 4 do 17 godina), odraslih s astmom (u dobi od 18 do 45 godina), odraslih s kroničnom opstruktivnom plućnom bolešću (KOPB) (starijih od 55 godina) i zdravih dobrovoljaca (u dobi od 18 do 45 godina) radi procjene brzine vršnog inspiratornog protoka (PIFR) i drugih povezanih inhalacijskih parametara nakon inhalacije iz inhalatora Spiromax (koji je sadržavao placebo) u usporedbi s inhalacijom iz multidoznog inhalatora sa suhim praškom već dostupnog na tržištu (koji je sadržavao placebo).
A randomised, open-label placebo study was performed in children and adolescents with asthma (aged 6-17 years), adults with asthma (aged 18-45 years), adults with chronic obstructive pulmonary disease (COPD – aged >50 years) and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device (containing placebo).
Randomizirano, otvoreno ispitivanje s placebom provedeno je na djeci i adolescentima s astmom (u dobi od 6-17 godina), odraslima s astmom (u dobi od 18-45 godina), odraslima s kroničnom opstruktivnom plućnom bolesti (KOPB– u dobi > 50 godina) i zdravim dobrovoljcima (u dobi od 18- 45 godina) za procjenu brzine vršnog inspiratornog protoka (eng. peak inspiratory flow rate, PIFR) i drugih povezanih inhalacijskih parametara nakon inhalacije iz inhalatora Spiromax (koji sadrži placebo) u usporedbi s inhalacijom iz već na tržištu dostupnog inhalatora s više doza suhog praška (koji sadrži placebo).
A randomised, open-label placebo study was performed in children and adolescents with asthma (aged 6-17 years), adults with asthma (aged 18-45 years), adults with chronic obstructive pulmonary disease (COPD – aged >50 years) and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device(containing placebo).
Randomizirano, otvoreno ispitivanje s placebom provedeno je na djeci i adolescentima s astmom (u dobi od 6-17 godina), odraslima s astmom (u dobi od 18- 45 godina), odraslima s kroničnom opstruktivnom plućnom bolesti (KOPB – u dobi > 50 godina) i zdravim dobrovoljcima (u dobi od 18- 45 godina) za procjenu brzine vršnog inspiratornog protoka (eng. peak inspiratory flow rate, PIFR) i drugih povezanih inhalacijskih parametara nakon inhalacije iz inhalatora Spiromax (koji sadrži placebo), u usporedbi s inhalacijom iz već na tržištu dostupnog inhalatora s više doza suhog praška (koji sadrži placebo).
A randomised, open-label placebo study was performed in children and adolescents with asthma (aged 6-17 years), adults with asthma (aged 18-45 years), and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device (containing placebo).
Randomizirano, otvoreno ispitivanje s placebom provedeno je na djeci i adolescentima s astmom (u dobi od 6-17 godina), odraslima s astmom (u dobi od 18- 45 godina) i zdravim dobrovoljcima (u dobi od 18-45 godina) za procjenu brzine vršnog inspiratornog protoka (eng. peak inspiratory flow rate, PIFR) i drugih povezanih inhalacijskih parametara nakon inhalacije iz inhalatora Spiromax (koji sadrži placebo), u usporedbi s inhalacijom iz već na tržištu dostupnog inhalatora s više doza suhog praška (koji sadrži placebo).
A randomised, open-label placebo study was performed in children and adolescents with asthma (aged 6-17 years), adults with asthma (aged 18-45 years)and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device (containing placebo).
Randomizirano, otvoreno ispitivanje s placebom provedeno je na djeci i adolescentima s astmom (u dobi od 6-17 godina), odraslima s astmom (u dobi od 18-45 godina) i zdravim dobrovoljcima (u dobi od 18-45 godina) za procjenu brzine vršnog inspiratornog protoka (eng. peak inspiratory flow rate, PIFR) i drugih povezanih inhalacijskih parametara nakon inhalacije iz inhalatora Spiromax (koji sadrži placebo) u usporedbi s inhalacijom iz već na tržištu dostupnog inhalatora s više doza suhog praška (koji sadrži placebo).
A randomised, open-label study was conducted to evaluate the efficacy and safety of Empliciti in combination with lenalidomide and dexamethasone in patients with multiple myeloma who have received one to three prior therapies.
Provedeno je randomizirano otvoreno ispitivanje radi ocjenjivanja djelotvornosti i sigurnosti lijeka Empliciti u kombinaciji s lenalidomidom i deksametazonom u bolesnika s multiplim mijelomom koji su prethodno primili jednu do tri terapije.
A randomised, open-label, multicentre study of 1,053 patients evaluated the efficacy of bevacizumab and oxaliplatin- or irinotecan-containing chemotherapeutic regimens with and without Vectibix in the first-line treatment of metastatic colorectal cancer.
U randomiziranom, otvorenom, multicentričnom ispitivanju na 1053 bolesnika praćena je djelotvornost kemoterapijskih protokola koji uključuju bevacizumab i oksaliplatin ili irinotekan u kombinaciji sa ili bez lijeka Vectibix u prvoj liniji liječenja bolesnika s metastatskim kolorektalnim karcinomom.
A randomized, double-blind study was conducted to assess the safety and efficacy of abatacept or infliximab versus placebo in patients with an inadequate response to methotrexate (Study V).
Provedeno je randomizirano, dvostruko slijepo ispitivanje sigurnosti i djelotvornosti abatacepta ili infliksimaba naspram placeba u bolesnika koji nisu dovoljno dobro odgovorili na metotreksat (Ispitivanje V).
A randomized, double-blind study was conducted to assess the safety and efficacy of intravenous abatacept or infliximab versus placebo in patients with an inadequate response to methotrexate (Study V).
Provedeno je randomizirano, dvostruko slijepo ispitivanje sigurnosti i djelotvornosti intravenski infliksimaba naspram placeba u bolesnika koji nisu dovoljno dobro odgovorili na metotreksat (Ispitivanje V).
A randomized, double-blind, placebo controlled study was conducted in 103 clinically stable subjects with PAH (WHO FC II and III) who were on bosentan therapy for a minimum of three months.
Randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno je u 103 klinički stabilnih bolesnika s PAH-om (WHO FC II i III) koji su se liječili bosentanom najmanje tri mjeseca.
A randomized, double-blind, placebo controlled study was conducted in 103 clinically stable subjects with PAH (WHO FC II and III) who were on bosentan therapy for a minimum of three months.
Randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno je u 103 kliničkih stabilnih bolesnika s PAH-om (WHO FC II i III) koji su se liječili bosentanom najmanje tri mjeseca.
A randomized, double-blind, placebo controlled study was conducted in 103 clinically stable subjects with PAH (WHO FC II and III) who were on bosentan therapy for a minimum of three months.
Randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno je u 103 kliničkih stabilnih bolesnika s PAH-om (WHO II i III) koji su se liječili bosentanom najmanje tri mjeseca.
A randomized, double-blind, placebo--controlled study (Study 58) was conducted to demonstrate safety and efficacy of vandetanib 300 mg versus placebo.
Randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje (Ispitivanje 58) provedeno je s ciljem da se pokažu sigurnost primjene i djelotvornost vandetaniba u dozi od 300 mg u odnosu na placebo.
A randomized, double-blind, placebo-controlled study (Study 58) was conducted to demonstrate safety and efficacy of vandetanib 300 mg versus placebo.
Randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje (Ispitivanje 58) provedeno je s ciljem da se pokažu sigurnost primjene i djelotvornost vandetaniba u dozi od 300 mg u odnosu na placebo.
A randomized, single(investigator)-blinded, non-inferiority study was conducted to assess the safety and efficacy of weekly subcutaneous (SC) abatacept without an abatacept intravenous (IV) loading dose versus every-other-weekly subcutaneous adalimumab, both with background MTX, in patients with an inadequate response to methotrexate (Study SC-II).
Randomizirano, jednostruko (za ispitivača) slijepo ispitivanje neinferiornosti provedeno je s ciljem ocjenjivanja sigurnosti i djelotvornosti abatacepta primijenjenog supkutano (s.c.) jedanput na tjedan bez intravenske (i.v.) udarne doze abatacepta naspram adalimumaba primijenjenog supkutano jedanput svaka dva tjedna u bolesnika koji nisu dovoljno dobro odgovorili na metotreksat; oba lijeka primjenjivala su se uz osnovnu terapiju MTX-om (Ispitivanje SC-II).
A rapid and sustained decrease in the levels of the inflammatory biomarkers; serum amyloid A (SAA), C- reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and a normalization of inflammatory hematological changes are seen.
Primijećeno je brzo i trajno smanjenje razina upalnih biomarkera; serumskog amiloida A (SAA), C- reaktivnog proteina (CRP) i brzine sedimentacije eritrocita te normalizacija upalnih hematoloških parametara.
A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira.
U bolesnika s poliartikularnim juvenilnim idiopatskim artritisom, Crohnovom bolešću, ulceroznim kolitisom i gnojnim hidradenitisom primijećeno je naglo smanjenje razina CRP-a nakon liječenja lijekom Humira.
A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic arthritis, Crohn’s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira.
U bolesnika s poliartikularnim juvenilnim idiopatskim artritisom, Crohnovom bolešću, ulceroznim kolitisom i gnojnim hidradenitisom primijećeno je naglo smanjenje razina CRP-a nakon liječenja lijekom Humira.
A rapid return of fertility is likely following treatment with ellaOne for emergency contraception.
Nakon primjene ellaOne kao hitne kontracepcije vjerojatan je brzi oporavak plodnosti.
A rapidly flashing orange status light indicates that an error has occurred.
Brzo treperenje narančaste lampice statusa znači da je došlo do pogreške.
A rare bowel condition called ‘fibrosing colonopathy’, where the intestine is narrowed, has been reported in patients with cystic fibrosis taking high doses of pancreatic enzymes.
Rijetka bolest crijeva koja se naziva "fibrozirajuća kolonopatija", u kojoj su crijeva sužena, prijavljena je u bolesnika s cističnom fibrozom koji uzimaju velike doze enzima gušterače.
A rare neurological side effect named posterior reversible encephalopathy syndrome (PRES) has been associated with Avastin treatment.
Liječenje lijekom Avastin, povezano je s rijetkom neurološkom nuspojavom koju nazivamo sindrom reverzibilne posteriorne encefalopatije.
a rare severe muscle disorder (rhabdomyolysis) which causes pain, tenderness and weakness of the muscles and may lead to kidney problems.
rijedak, teški mišićni poremećaj (rabdomioliza) koji uzrokuje bol, osjetljivost i slabost mišića i može dovesti do problema s bubrezima.
A rare side effect that may show up in blood tests is: an increase in an enzyme called amylase.
Rijetka nuspojava koja se može otkriti krvnim pretragama je: povišena vrijednost enzima amilaze.
A rare side effect that may show up in blood tests is: increase in an enzyme called amylase.
Rijetka nuspojava koja se može otkriti krvnim pretragama je: povišena vrijednost enzima amilaze.
a rare type of anaemia in which the red blood cells, white blood cells and platelets are all reduced in number (aplastic anaemia);
rijetka vrsta anemije u kojoj je snižen broj crvenih krvnih stanica, bijelih krvnih stanica i trombocita (aplastična anemija);
a rash
osip
A rash.
Osip.
a Rate adjusted for stratification factors (baseline usage of OCS and geographical region). b CI = Confidence interval
a Stopa prilagođena za stratifikacijske čimbenike (početna uporaba peroralnih kortikosteroida i geografska regija). b CI = interval pouzdanosti
A ratio of ~2400 and ~1300 was required for C. albicans and C. glabrata, respectively, in these models.
Na tim se modelima pokazalo da je omjer potreban za C. albicans 2400, a za C.glabrata 1300.
A reaction at the site where the injection was given high blood sugar
reakcije na mjestu primjene injekcije. visok šećer u krvi.
A reaction at the site where the injection was given. high blood sugar
reakcije na mjestu primjene injekcije. visok šećer u krvi.
A realistic goal is to lose between 5% to 10% of your starting weight.
Realni je cilj početnu tjelesnu težinu smanjiti za 5 do 10 %.
A recent co-registered computed tomography (CT) scan or magnetic resonance (MR) imaging of the patient to get a fused PET-CT or PET-MR image is recommended in cases of uncertainty about the location of grey matter and of the grey/white matter border in the PET scan (see section 4.4. Image interpretation).
Ako se na PET snimci ne može sa sigurnošću odrediti lokacija sive tvari te granica između sive i bijele tvari, preporučuje se PET snimku fuzionirati s nedavno učinjenim snimkama kompjuterizirane tomografije (CT) ili magnetske rezonancije (MR) kako bi se dobila kombinirana PET-CT ili PET-MR snimka (vidjeti dio 4.4 Interpretacija snimke).
A recent co-registered computed tomography (CT) scan or magnetic resonance (MR) imaging of the patient to get a fused PET-CT or PET-MR image is recommended in cases of uncertainty about the location of grey matter and of the grey/white matter border in the PET scan (see section 4.4. Interpretation of Neuraceq images).
Ako se na slikama dobivenim PET-om ne može sa sigurnošću lokalizirati siva tvar te odrediti granica između sive i bijele tvari, preporučuje se slike dobivene PET-om fuzionirati s nedavno učinjenom slikom kompjuterizirane tomografije (CT) ili magnetske rezonancije (MR) kako bi se dobila kombinirana slika PET-CT ili PET-MR (vidjeti dio 4.4 Tumačenja slika pri primjeni Neuraceqa).
A recent heart attack, heart disease, sick sinus syndrome, (abnormal heart rhythms), unstable angina or low blood pressure
imali ste nedavno srčani udar, imate bolest srca, sindrom bolesnog sinusa, (abnormalni srčani ritmovi), nestabilnu anginu ili niski krvni tlak
a recent serious injury
ako ste nedavno imali ozbiljnu ozljedu
a recent serious injury
nedavne ozbiljne ozljede
a recent serious injury
nedavne teške ozljede
a recent serious injury
nedavne teške ozljede,
a recent serious injury.
nedavne teške ozljede,
a recent serious injury.
nedavne teške ozljede.
a recent surgery (including dental)
nedavnog kirurškog zahvata (uključujući stomatološke zahvate)
a recent surgery (including dental).
nedavnog kirurškog zahvata (uključujući stomatološke zahvate),
a recent surgery (including dental).
nedavnog kirurškog zahvata (uključujući stomatološke zahvate).
A red film-coated, oval, biconvex, beveled edge tablet marked with “ME” on one side of the tablet and “20” on the other side.
Filmom obložene, ovalne, bikonveksne tablete s ukošenim rubom i oznakom »ME« na jednoj strani tablete i »20« na drugoj strani.
A reduced number of infection-fighting cells in the blood (white blood cells)
manjeni broj stanica koje suzbijaju infekciju u krvi (bijele krvne stanice)
a reduced number of platelets in the blood (thrombocytopenia) which are important to stop bleeding and work by clumping and clotting blood vessel injuries gastrointestinal problems.
manjenje broja trombocita u krvi (trombocitopenija) koje su važne u zaustavljanju krvarenja i koji djeluju tako da se skupljaju i stvaraju ugrušak kod oštećenih krvnih žila. poteškoće sa želucem i crijevima
a reduced number of red blood cells (anaemia)
manjenje broja crvenih krvnih stanica (anemija)
A reduced starting dose of ONIVYDE (liposomal irinotecan) of 60 mg/ m2 should be considered for patients known to be homozygous for the UGT1A1*28 allele (see sections 4.8 and 5.1).
Za bolesnike za koje je poznato da su homozigoti za alel UGT1A1*28 potrebno je razmotriti smanjenu početnu dozu lijeka ONIVYDE (liposomalni irinotekan) od 60 mg/m2 (vidjeti dijelove 4.8 i 5.1).
A reduced virological response was observed in patients with viral strains harbouring two or more mutations at HIV protease codons 33, 82, 84 or 90, and not receiving new enfuvirtide.
Smanjena virološka reakcija primijećena je u bolesnika s virusnim sojevima s dvije ili više mutacija u proteaznim kodonima 33, 82, 84 ili 90, koji ne primaju novi enfuvirtid.
A reduction (up to 0.3 MU/L from a baseline median of 2.5 MU/L) in median thyroid-stimulating hormone was observed at most visits in the selexipag group.
Smanjenje (do 0,3 mU/l od početnog medijana od 2,5 mU/l) medijana razine hormona koji stimulira štitnjaču uočeno je na većini posjeta u skupini koja je primala seleksipag.
A reduction in bazedoxifene exposure may be associated with an increased risk of endometrial hyperplasia.
Smanjeno izlaganje bazedoksifenu može biti povezano s povećanim rizikom od hiperplazije endometrija.